ABSTRACT Pathologic and experimental evidence indicates that platelet activation and fibrin formation contribute to the pathogenesis of angina pectoris, coronary vasospasm and myocardial infarction. Detection of localized intravascular platelet activation and fibrin formation in vivo by selective blood sampling requires catheters that do not induce coagulation ex vivo. We studied the effect of heparin bonding of catheter surfaces on activation of the coagulation system by cardiovascular catheters. Woven Dacron, polyvinylchloride, and polyurethane catheters were tested and compared with identical catheters with heparin-bonded surfaces in 47 patients undergoing percutaneous cardiac catheterization. Platelet activation was measured by radioimmunoassay of plasma platelet factor 4 (PF4), /3-thromboglobulin (BTG), and thromboxane B2 (TXB2) in blood samples withdrawn through catheters, and fibrin formation was assessed by determination of fibrinopeptide A (FPA) levels. In blood samples collected through conventional catheters, FPA, PF4, BTG, and TXB2 levels were markedly elevated; blood sampling through heparin-bonded catheters had no significant effect on FPA, PF4, BTG, or TXB2 levels. Scanning electron microscopy disclosed extensive platelet aggregates and fibrin strands adherent to the surface of conventional catheters but not to heparin-bonded catheter surfaces. This study demonstrates that (1) collection of blood samples through cardiovascular catheters causes artifactual elevation of FPA, PF4, BTG, and TXB2 levels, and (2) heparin-bonded catheter surfaces effectively prevent catheter-induced platelet a-granule release and fibrin formation on catheter surfaces. Heparin-bonded catheters will facilitate investigation of the role of intravascular coagulation in coronary artery disease by eliminating catheter-induced fibrin formation and platelet activation. Circulation 70, No. 5, 843-850, 1984. RECENT clinical and experimental evidence suggests that platelet activation and fibrin formation in vivo may be fundamentally important in clinical complications of atherosclerotic coronary artery disease, including unstable angina,1 myocardial infarction,24 and sudden death.5 Investigation of platelet release and fibrin formation in vivo has been facilitated by the recent development of radioimmunoassays for specific proteins and prostanoids released by activated platelets6'7 and peptides released during fibrin formation.8
RECENT clinical and experimental evidence suggests that platelet activation and fibrin formation in vivo may be fundamentally important in clinical complications of atherosclerotic coronary artery disease, including unstable angina,1 myocardial infarction,24 and sudden death.5 Investigation of platelet release and fibrin formation in vivo has been facilitated by the recent development of radioimmunoassays for specific proteins and prostanoids released by activated platelets6'7 and peptides released during fibrin formation.8
Platelet factor 4 (PF4) and ,3-thromboglobulin (BTG) are platelet-specific proteins secreted from platelet agranules during the platelet-release reaction.9 10 Thromboxane B2 (TXB2) is the stable metabolite of TXA2, a vasoactive prostanoid-eicosanoid released by aggregating platelets." Fibrinopeptide A (FPA) is a 16-amino acid peptide that is cleaved from fibrinogen by thrombin and reflects fibrin I formation. '2 Studies in our laboratory have shown that plasma levels of these products in peripheral venous blood are within the normal range in most patients with coronary artery disease, both when they are at rest'3 and during exercise-induced myocardial ischemia. 1'4 These studies, however, do not exclude the possibility that significant release of these products into the coronary circulation may be undetectable in peripheral venous blood. Detection of platelet activation and fibrin formation in the coronary circulation requires selective blood sampling directly from the coronary sinus. Several groups of investigators have reported elevated BTG'5 and TXB216-'9 levels in coronary sinus blood of patients with coronary artery disease and have interpreted these data as evidence for intracoronary platelet activation.
Meticulous blood sampling technique is essential to avoid spurious elevation of FPA, PF4, BTG, and TXB2 levels ex vivo.20 An Effect of catheter insertion. After insertion of control catheters, peripheral FPA levels rose to 9.4 nM (figure 1), which was significantly higher (p < .05) than the 3.4 nM level observed after sheath insertion. After insertion of heparin-bonded catheters, the mean FPA level in peripheral venous blood was 3.4 nM (figure 1), which was not different from the level resulting after sheath insertion. Peripheral venous levels of PF4, BTG, and TXB2 were not significantly different after insertion of either heparin-bonded or conventional catheters (figures 2 to 4).
The effect of indwelling catheters on peripheral venous blood levels was assessed by comparing peripheral levels immediately after catheter insertion with levels observed 30 min later. The elevated FPA levels, which were observed immediately after insertion of control catheters, persisted but did not increase further figure 1 ). In contrast, FPA levels in serial blood samples collected through heparin-bonded catheters were not significantly elevated compared with levels in peripheral venous blood either 5 min after catheter insertion or 30 min later (figure 1).
Five minutes after catheter insertion, PF4 levels in blood collected through control catheters were elevated (11 .2 ng/ml) compared with levels in peripheral venous blood (6.9 ng/ml), but this difference was not significant (figure 2). Thirty minutes later PF4 levels (46.3 ng/ml) were significantly (p < .01) elevated above the corresponding venous level (6.7 ng/ml). PF4 levels were not elevated in blood collected through heparin-bonded catheters compared with those in peripheral venous blood (figure 2).
BTG levels were Qignificantly (p < .01) elevated (48.3 ng/ml) in catheter samples collected after insertion of control catheters compared with venous levels (27.5 ng/ml), and rose progressively over the next 30 min to 108.7 ng/ml (figure 3). In blood collected through heparin-bonded catheters, BTG levels were not elevated during the 30 min period. TXB2 levels were elevated in blood samples drawn through control catheters 5 min after catheter insertion (mean 157.1 pg/ml) compared with the levels in peripheral venous blood (99.4 pg/ml) but this difference did not reach statistical significance. After 30 min TXB, levels were markedly elevated (557.8 pg/ml) in catheter samples compared with those in peripheral venous blood (1 1 1.6 pg/ml; figure 4) . In blood collected through heparin-bonded catheters TXB2 levels were not elevated during the 30 min period and were not significantly different from levels in simultaneously collected peripheral blood. DIAGNOSTIC METHODS-ImROMBOEMBOLIC DISEASE gregates and trapped red cells was observed on the inside surfaces of all of these catheters. Scanning electron micrographs of surfaces of heparin-bonded catheters showed no fibrin strands or platelet aggregates (figure 6).
Effect of catheter insertion over guidewires. Shown in figure 7 are mean FPA, PF4, BTG, and TXB, levels for five patients in whom heparin-bonded polyurethane coronary catheters were inserted over 145 cm guidewires. Levels in this subgroup were significantly elevated, as measured in blood samples collected through the catheters 5 min after insertion. Over the ensuing 30 min, FPA, PF4, BTG, and TXBW levels gradually declined.
Discussion
Clinical studies suggest that platelet activation and aggregation, thromboxane generation, and fibrin formation in the coronary circulation may have important roles in unstable angina, variant angina, sudden death, and coronary thrombosis. 1-5. 25 Several groups of investigators have reported that levels of TXB, the stable metabolite of TXA,, are elevated in coronary sinus blood of patients with variant angina.61 --Other investigators have reported elevated TXB2 levels in coronary sinus blood of patients with coronary artery disease after episodes of spontaneous angina, 17 19 in association with pacing-induced angina, 16 or within 24 hr of an episode of chest pain.27 Elevated BTG levels have been reported in coronary sinus blood of patients with coronary artery disease and have been interpreted as demonstrating abnormal platelet activation in the atherosclerotic coronary circulation. '5 In all these studies, blood samples were collected from the coronary sinus with woven Dacron catheters. As shown in the present study, mean FPA levels in peripheral venous blood increased significantly immediately after insertion of catheters of this type. Mean FPA levels in blood drawn through the woven Dacron catheters were significantly elevated above those in simultaneously drawn peripheral venous samples after catheter insertion and rose significantly to very high levels over 30 min. These data suggest that fibrin formation was occurring on the outside and inside surfaces of the woven Dacron catheters, and this was confirmed by electron micrographs that showed fibrin strands adherent to the internal catheter surfaces. Although levels in peripheral venous blood did not change, the levels of PF4, BTG, and TXB, in samples withdrawn through the conventional catheters were also significantly elevated above levels measured simultaneously in venous blood; all three rose progres- sively and markedly over 30 min. These data suggest that platelet activation occurred as blood was withdrawn through the woven Dacron catheters. Scanning electron micrographs confirmed the presence of aggre- 
ed catheters is additional evidence that the antithrombotic effect of these catheters does not result from local heparin desorption, since heparin administered intravenously elevates PF4 levels markedly. 33 An advantage of the use of heparin-bonded catheters for investigative studies is that the need for systemic heparinization is eliminated. Systemic heparinization is routinely used during most cardiac catheterization and angiographic procedures to prevent catheter-induced thromboembolic complications. For investigative studies of intravascular platelet activation and fibrin formation, systemic heparinization is disadvantageous for the following reasons. First, heparin elevates PF4 levels markedly, possibly by displacing PF4 bound to vascular endothelium,33 second, heparin inhibits thrombin action and promptly reduces FPA levels to the normal range,34 and third, heparin may affect platelets directly, altering either aggregation or activation. 35' 36 Several techniques of percutaneous catheter insertion were also evaluated and found to affect FPA, PF4, PTG, and TXB2 levels significantly. Insertion of vascular sheaths caused slight but significant elevation of FPA in peripheral venous blood. Insertion of heparinbonded coronary catheters over 145 cm heparin-coated guidewires into the femoral artery by the Seldinger technique22 resulted in immediate elevation of FPA, PF4, BTG, and TXB2 levels in blood withdrawn through the catheters. This observation suggested that the guidewires reversed the passivating effect of the heparin coating, possibly by abrading the inner surface of the catheters. Direct insertion of catheters through sheaths placed percutaneously eliminated the need for guidewires and did not elevate PF4, BTG, or TXB2 either in peripheral venous blood or in blood samples collected through the catheters.
The results of the present study indicate that heparin-bonded catheters will be useful for selective intravascular blood sampling without artifactual activation of platelets or marked formation of fibrin. This approach will facilitate detection and localization of intravascular platelet release and fibrin formation in future investigations. Both venous and arterial catheters can be effectively heparin-bonded, making it possible to detect platelet release regionally in the coronary, cerebrovascular, renal, or peripheral circulations.
